Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Guo, Yelei ^a   Wang, Yao ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE FUNCTION; NONHUMAN; REVIEW; SOLID TUMOR; STROMA; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; NEOPLASMS; TRANSPLANTATION;

ANIMALS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84960977283     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/3850839     Document Type: Review

References (106)

1. M. H. Kershaw, J. A. Westwood, and P. K. Darcy, "Geneengineered T cells for cancer therapy," Nature Reviews Cancer, vol. 13, no. 8, pp. 525-541, 2013.
2. M. Sadelain, R. Brentjens, and I. Rivière, "The basic principles of chimeric antigen receptor design," Cancer Discovery, vol. 3, no. 4, pp. 388-398, 2013.
3. J. N. Kochenderfer, M. E. Dudley, S. H. Kassim et al., "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor," Journal of Clinical Oncology, vol. 33, no. 6, pp. 540-549, 2015.
4. J. N. Kochenderfer, M. E. Dudley, S. A. Feldman et al., "B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimericantigen-receptor-transduced T cells," Blood, vol. 119, no. 12, pp. 2709-2720, 2012.
5. C. U. Louis, B. Savoldo, G. Dotti et al., "Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma," Blood, vol. 118, no. 23, pp. 6050-6056, 2011.
6. R. J. Brentjens, M. L. Davila, I. Riviere et al., "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia," Science Translational Medicine, vol. 5, no. 177, Article ID 177ra38, 2013.
7. C. H. J. Lamers, S. Sleijfer, A. G. Vulto et al., "Treatment of metastatic renal cell carcinomawith autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience," Journal of Clinical Oncology, vol. 24, no. 13, pp. e20-e22, 2006.
8. C. H. J. Lamers, S. Sleijfer, S. Van Steenbergen et al., "Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity," MolecularTherapy, vol. 21, no. 4, pp. 904-912, 2013.
9. J. R. Park, D. L. Digiusto, M. Slovak et al., "Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma,"MolecularTherapy, vol. 15, no. 4, pp. 825-833, 2007.
10. G. Gross, T. Waks, and Z. Eshhar, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 24, pp. 10024-10028, 1989.
11. M. H. Kershaw, J. A. Westwood, L. L. Parker et al., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer," Clinical Cancer Research, vol. 12, no. 20, pp. 6106-6115, 2006.
12. M. A. Pule, B. Savoldo, G. D. Myers et al., "Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma," Nature Medicine, vol. 14, no. 11, pp. 1264-1270, 2008.
13. R. A. Morgan, J. C. Yang, M. Kitano,M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, "Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2," Molecular Therapy, vol. 18, no. 4, pp. 843-851, 2010.
14. G. L. Beatty, A. R. Haas, M. V. Maus et al., "Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies," Cancer Immunology Research, vol. 2, no. 2, pp. 112-120, 2014.
15. N. Ahmed, V. S. Brawley, M. Hegde et al., "Human Epidermal Growth Factor Receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma," Journal of Clinical Oncology, vol. 33, no. 15, pp. 1688-1696, 2015.
16. M. V. Maus, A. R. Haas, G. L. Beatty et al., "T cells expressing chimeric antigen receptors can cause anaphylaxis in humans," Cancer Immunology Research, vol. 1, pp. 26-31, 2013.
17. S. C. Katz, R. A. Burga, E. McCormack et al., "Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases," Clinical Cancer Research, vol. 21, no. 14, pp. 3149-3159, 2015.
18. X. Tang, Y. Zhou, W. Li et al., "T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo," Journal of Biomedical Research, vol. 28, no. 6, pp. 468-475, 2014.
19. G. Jakka, P. C. Schuberth, M. Thiel et al., "Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system," Anticancer Research, vol. 33, no. 10, pp. 4189-4201, 2013.
20. N. Ahmed, V. S. Salsman, E. Yvon et al., "Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression," Molecular Therapy, vol. 17, no. 10, pp. 1779-1787, 2009.
21. D. Ebb, P. Meyers, H. Grier et al., "Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report fromthe children's oncology group," Journal of Clinical Oncology, vol. 30, no. 20, pp. 2545-2551, 2012.
22. M. Sadelain, R. Brentjens, and I. Rivière, "The promise and potential pitfalls of chimeric antigen receptors," Current Opinion in Immunology, vol. 21, no. 2, pp. 215-223, 2009.
23. S. Kakarla and S. Gottschalk, "CAR T cells for solid tumors: armed and ready to go" Cancer Journal, vol. 20, no. 2, pp. 151-155, 2014.
24. P. G. Coulie, B. J. Van den Eynde, P. van der Bruggen, and T. Boon, "Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy," Nature Reviews Cancer, vol. 14, no. 2, pp. 135-146, 2014.
25. N. Vigneron, V. Stroobant, B. J. Van den Eynde, and P. van der Bruggen, "Database of T cell-defined human tumor antigens: the 2013 update," Cancer Immunity, vol. 13, article 15, 2013.
26. E. F. Fritsch, N. Hacohen, and C. J. Wu, "Personal neoantigen cancer vaccines: the momentum builds," Oncoimmunology, vol. 3, no. 6, Article ID e29311, 2014.
27. J. H. Sampson, A. B. Heimberger, G. E. Archer et al., "Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma," Journal of Clinical Oncology, vol. 28, no. 31, pp. 4722-4729, 2010.
28. T. Blankenstein, M. Leisegang, W. Uckert, and H. Schreiber, "Targeting cancer-specific mutations by T cell receptor gene therapy," Current Opinion in Immunology, vol. 33, pp. 112-119, 2015.
29. F. Turatti, M. Figini, E. Balladore et al., "Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction," Journal of Immunotherapy, vol. 30, no. 7, pp. 684-693, 2007.
30. M. Chmielewski, A. Hombach, C. Heuser, G. P. Adams, and H. Abken, "T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigenpositive target cells but decreases selectivity," The Journal of Immunology, vol. 173, no. 12, pp. 7647-7653, 2004.
31. X. Liu, S. Jiang, C. Fang et al., "Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice," Cancer Research, vol. 75, no. 17, pp. 3596-3607, 2015.
32. H. G. Caruso, L. V. Hurton, A. Najjar et al., "Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity," Cancer Research, vol. 75, no. 17, pp. 3505-3518, 2015.
33. C. H. J. Lamers, R. Willemsen, P. van Elzakker et al., "Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells," Blood, vol. 117, no. 1, pp. 72-82, 2011.
34. A. H. Long, W. M. Haso, J. F. Shern et al., "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors," Nature Medicine, vol. 21, no. 6, pp. 581-590, 2015.
35. H. Zhang, K. M. Snyder,M. M. Suhoski et al., "4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy," The Journal of Immunology, vol. 179, no. 7, pp. 4910-4918, 2007.
36. C. Carpenito, M. C. Milone, R. Hassan et al., "Control of large, established tumor xenograftswith genetically retargeted human T cells containingCD28 and CD137 domains," Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 106, no. 9, pp. 3360-3365, 2009.
37. X.-S. Zhong, M. Matsushita, J. Plotkin, I. Riviere, and M. Sadelain, "Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3 kinase/AKT/Bcl-X activation and CD8+ T cell-mediated tumor eradication,"Molecular Therapy, vol. 18, no. 2, pp. 413-420, 2010.
38. A. A. Hombach, G. Rappl, and H. Abken, "Arming cytokineinduced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 super-stimulation'," MolecularTherapy, vol. 21, no. 12, pp. 2268-2277, 2013.
39. Y. Zhao, Q. J. Wang, S. Yang et al., "A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity," The Journal of Immunology, vol. 183, no. 9, pp. 5563-5574, 2009.
40. S. L. Maude, N. Frey, P. A. Shaw et al., "Chimeric antigen receptor T cells for sustained remissions in leukemia," The New England Journal ofMedicine, vol. 371, no. 16, pp. 1507-1517, 2014.
41. D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson et al., "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial," The Lancet, vol. 385, no. 9967, pp. 517-528, 2015.
42. M. C. Milone, J. D. Fish, C. Carpenito et al., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo," MolecularTherapy, vol. 17, no. 8, pp. 1453-1464, 2009.
43. C. M. Kowolik, M. S. Topp, S. Gonzalez et al., "CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells," Cancer Research, vol. 66, no. 22, pp. 10995-11004, 2006.
44. H. M. Finney, A. N. Akbar, and A. D. G. Lawson, "Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals fromthe TCR chain," The Journal of Immunology, vol. 172, no. 1, pp. 104-113, 2004.
45. C. S. Hinrichs, Z. A. Borman, L. Cassard et al., "Adoptively transferred effector cells derived from naüve rather than central memory CD8+ T cells mediate superior antitumor immunity," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 41, pp. 17469-17474, 2009.
46. C. A. Klebanoff, L. Gattinoni, P. Torabi-Parizi et al., "Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9571-9576, 2005.
47. C. H. J. Lamers, S. van Steenbergen-Langeveld, M. van Brakel et al., "T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness," Human Gene Therapy Methods, vol. 25, no. 6, pp. 345-357, 2014.
48. C. S. Hinrichs, R. Spolski, C. M. Paulos et al., "IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy," Blood, vol. 111, no. 11, pp. 5326-5333, 2008.
49. S. Kaneko, S. Mastaglio, A. Bondanza et al., "IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive selfrenewing central memory human T lymphocytes," Blood, vol. 113, no. 5, pp. 1006-1015, 2009.
50. N. Pouw, E. Treffers-Westerlaken, A. Mondino, C. Lamers, and R. Debets, "TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity," Molecular Immunology, vol. 47, no. 7-8, pp. 1411-1420, 2010.
51. C. E. Brown, R. P. Vishwanath, B. Aguilar et al., "Tumorderived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells," The Journal of Immunology, vol. 179, no. 5, pp. 3332-3341, 2007.
52. U. Palendira, R. Chinn, W. Raza et al., "Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow," Blood, vol. 112, no. 8,pp. 3293-3302, 2008.
53. B. Jena, G. Dotti, and L. J. N. Cooper, "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor," Blood, vol. 116, no. 7, pp. 1035-1044, 2010.
54. M. H. Kershaw, G. Wang, J. A. Westwood et al., "Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2," Human Gene Therapy, vol. 13, no. 16, pp. 1971-1980, 2002.
55. A. Di Stasi, B. De Angelis, C. M. Rooney et al., "T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model," Blood, vol. 113, no. 25, pp. 6392-6402, 2009.
56. M. D. Vesely, M. H. Kershaw, R. D. Schreiber, andM. J. Smyth, "Natural innate and adaptive immunity to cancer," Annual Review of Immunology, vol. 29, pp. 235-271, 2011.
57. J. A. Joyce andD. T. Fearon, "T cell exclusion, immune privilege, and the tumor microenvironment," Science, vol. 348, no. 6230, pp. 74-80, 2015.
58. P. Sharma and J. P. Allison, "The future of immune checkpoint therapy," Science, vol. 348, no. 6230, pp. 56-61, 2015.
59. F. Liu,R. Lang, J. Zhaoet al., "CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival andmolecular subtypes," Breast Cancer Research and Treatment, vol. 130, no. 2, pp. 645-655, 2011.
60. T. H. Kang, C.-P. Mao, S. Y. Lee et al., "Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity," Cancer Research, vol. 73, no. 8, pp. 2493-2504, 2013.
61. P. Muranski, A. Boni, C. Wrzesinski et al., "Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go"Nature Clinical PracticeOncology, vol. 3, no. 12, pp. 668-681, 2006.
62. M. Anraku, T. Tagawa, L. Wu et al., "Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma," The Journal of Immunology, vol. 185, no. 2, pp. 956-966, 2010.
63. C. T. Garnett, J. Schlom, and J. W. Hodge, "Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement," Clinical Cancer Research, vol. 14, no. 11, pp. 3536-3544, 2008.
64. K. L. Knutson, Y. Dang,H. Lu et al., "IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neutransgenic mice," The Journal of Immunology, vol. 177, no. 1, pp. 84-91, 2006.
65. G. C. Cesana, G. DeRaffele, S. Cohen et al., "Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma," Journal of Clinical Oncology, vol. 24, no. 7, pp. 1169-1177, 2006.
66. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes," Science, vol. 298, no. 5594, pp. 850-854, 2002.
67. E. B. Golden, I. Pellicciotta, S. Demaria, M. H. Barcellos-Hoff, and S. C. Formenti, "The convergence of radiation and immunogenic cell death signaling pathways," Frontiers in Oncology, vol. 2, article 88, Article ID Article 88, 2012.
68. D. R. Green, T. Ferguson, L. Zitvogel, and G. Kroemer, "Immunogenic and tolerogenic cell death," Nature Reviews Immunology, vol. 9, no. 5, pp. 353-363, 2009.
69. M. Obeid, T. Panaretakis, N. Joza et al., "Calreticulin exposure is required for the immunogenicity of y-irradiation and UVC light-induced apoptosis," Cell Death and Differentiation, vol. 14, no. 10, pp. 1848-1850, 2007.
70. M. Obeid, A. Tesniere, T. Panaretakis et al., "Ecto-calreticulin in immunogenic chemotherapy," Immunological Reviews, vol. 220, no. 1, pp. 22-34, 2007.
71. V. Shahabi,M. A. Postow,D. Tuck, and J. D. Wolchok, "Immunepriming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy," American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 38, no. 1, pp. 90-97, 2015.
72. L. Apetoh, F. Ghiringhelli, A. Tesniere et al., "Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy," Nature Medicine, vol. 13, no. 9, pp. 1050-1059, 2007.
73. B. C. Burnette, H. Liang, Y. Lee et al., "The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity," Cancer Research, vol. 71, no. 7, pp. 2488-2496, 2011.
74. Y. Lee, S. L. Auh, Y. Wang et al., "Therapeutic effects of ablative radiation on local tumor requireCD8+ T cells: changing strategies for cancer treatment," Blood, vol. 114, no. 3, pp. 589-595, 2009.
75. E. A. Reits, J. W. Hodge, C. A. Herberts et al., "Radiation modulates the peptide repertoire, enhancesMHC class I expression, and induces successful antitumor immunotherapy," Journal of Experimental Medicine, vol. 203, no. 5, pp. 1259-1271, 2006.
76. M. Chakraborty, S. I. Abrams, K. Camphausen et al., "Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy," The Journal of Immunology, vol. 170, no. 12, pp. 6338-6347, 2003.
77. M. G. Ruocco, K. A. Pilones, N. Kawashima et al., "Suppressing T cellmotility induced by anti-CTLA-4monotherapy improves antitumor effects,"The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3718-3730, 2012.
78. K. M. Mahoney, P. D. Rennert, andG. J. Freeman, "Combination cancer immunotherapy and new immunomodulatory targets," Nature Reviews Drug Discovery, vol. 14, no. 8, pp. 561-584, 2015.
79. N. A. Bhowmick, E. G. Neilson, and H. L. Moses, "Stromal fibroblasts in cancer initiation and progression," Nature, vol. 432, no. 7015, pp. 332-337, 2004.
80. A. Orimo, P. B. Gupta, D. C. Sgroi et al., "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion," Cell, vol. 121, no. 3, pp. 335-348, 2005.
81. A. M. Santos, J. Jung,N. Aziz, J. L. Kissil, and E. Puré, "Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice," The Journal of Clinical Investigation, vol. 119, no. 12, pp. 3613-3625, 2009.
82. T.-K. Ito, G. Ishii, H. Chiba, and A. Ochiai, "The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells," Oncogene, vol. 26, no. 51, pp. 7194-7203, 2007.
83. Y. Zhang, H. Tang, J. Cai et al., "Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion," Cancer Letters, vol. 303, no. 1, pp. 47-55, 2011.
84. Z. G. Fridlender, J. Sun, S. Kim et al., "Polarization of tumorassociated neutrophil phenotype by TGF-: 'N1' versus 'N2' TAN," Cancer Cell, vol. 16, no. 3, pp. 183-194, 2009.
85. E. Tran, D. Chinnasamy, Z. Yu et al., "Immune targeting of fibroblast activation protein triggers recognition ofmultipotent bone marrow stromal cells and cachexia," Journal of Experimental Medicine, vol. 210, no. 6, pp. 1125-1135, 2013.
86. S. Kakarla, K. K. H. Chow, M. Mata et al., "Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma," MolecularTherapy, vol. 21, no. 8, pp. 1611-1620, 2013.
87. P. C. Schuberth, C. Hagedorn, S. M. Jensen et al., "Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells," Journal of Translational Medicine, vol. 11, article 187, 2013.
88. L. S. Wang, A. Lo, J. Scholler et al., "Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity," Cancer Immunology Research, vol. 2, no. 2, pp. 154-166, 2014.
89. K. Fousek and N. Ahmed, "The Evolution of T-cell therapies for solid malignancies," Clinical Cancer Research, vol. 21, no. 15, pp. 3384-3392, 2015.
90. C. C. Kloss, M. Condomines,M. Cartellieri,M. Bachmann, and M. Sadelain, "Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells," Nature Biotechnology, vol. 31, no. 1, pp. 71-75, 2013.
91. V. D. Fedorov, M. Themeli, and M. Sadelain, "PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses," Science Translational Medicine, vol. 5, no. 215, Article ID 215ra172, 2013.
92. S. Srivastava and S. R. Riddell, "EngineeringCAR-T cells: design concepts," Trends in Immunology, vol. 36, no. 8, pp. 494-502, 2015.
93. Z. Grada, M. Hegde, T. Byrd et al., "TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy," MolecularTherapy- Nucleic Acids, vol. 2, article e105, 2013.
94. C. Yee, J. A. Thompson, D. Byrd et al., "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168-16173, 2002.
95. S. Khaleghi, F. Rahbarizadeh, D. Ahmadvand, M. J. Rasaee, and P. Pognonec, "A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells," International Journal of Hematology, vol. 95, no. 4, pp. 434-444, 2012.
96. V. Hoyos, B. Savoldo, C. Quintarelli et al., "Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety," Leukemia, vol. 24, no. 6, pp. 1160-1170, 2010.
97. L. E. Budde, C. Berger, Y. Lin et al., "Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma," PLoS ONE, vol. 8, no. 12, Article ID e82742, 2013.
98. G. J. Freeman, A. J. Long, Y. Iwai et al., "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 familymember leads to negative regulation of lymphocyte activation," The Journal of Experimental Medicine, vol. 192, no. 7, pp. 1027-1034, 2000.
99. H. Dong, S. E. Strome,D. R. Salomao et al., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion," Nature Medicine, vol. 8, no. 8, pp. 793-800, 2002.
100. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PDL1 blockade," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12293-12297, 2002.
101. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer," The New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
102. J. R. Brahmer, C. G. Drake, I. Wollner et al., "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates," Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167-3175, 2010.
103. S. L. Topalian, C. G. Drake, and D. M. Pardoll, "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity," CurrentOpinion in Immunology, vol. 24,no. 2, pp. 207-212, 2012.
104. I. Le Mercier, J. L. Lines, and R. J. Noelle, "Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators," Frontiers in Immunology, vol. 6, article 418, 2015.
105. A. G. Niethammer, H. Wodrich, M. Loeffler et al., "Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy," The FASEB Journal, vol. 19, no. 1, pp. 158-159, 2005.
106. P. Liu, L. Chen, and X. Huang, "The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo," Cancer Biotherapy Radiopharmaceuticals, vol. 24, no. 1, pp. 91-98, 2009.